Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

Cancer Immunology, Immunotherapy

Volumn 51, Issue 10, 2002, Pages 539-546

  Dréno, Brigitte ^a   Nguyen, Jean Michel ^b   Khammari, Amir ^a   Pandolfino, Marie ^c   Tessier, Marie ^a   Bercegeay, Sylvain ^c   Cassidanius, Alain ^c   Lemarre, Philippe ^c   Billaudel, Sylviane ^c   Labarrière, Nathalie ^d   Jotereau, Francine ^d  

^a HÔTEL DIEU   (France)

^b CHU DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Adjuvant therapy; Immunotherapy; Melanoma

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VERTIGO; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 0036034859     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0315-1     Document Type: Article

References (22)

1. Alexander-Miler MA, Leggatt GR, Sarin A, et al (1996) Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector, CTL. J Exp Med 184:485
2. Becker JC, Kampgen E, et al (2000) Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 25:503
3. Dalgleish A (1996) The case for therapeutic vaccines. Melanoma Res 6:5
4. Dillman RO, Oldham RK, Barth NM, et al (1991) Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68:1
5. Goedegebuure PS, Douville LM, Li H, et al (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 13:1939
6. Granziero L, Krajewski S, Farness P, et al (1999) Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 29:1127
7. Greenberg PD (1991) Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
8. + T cell adoptive immunotherapy. Immunity 13:265
9. Jotereau F, Pandolfino MC, Boudart D, et al (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405
10. Kawakami Y, Eliyahu S, Jennings C, et al (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961
11. Matthews JNS, Altman DG (1996) Statistics notes: Interactions 3: How to examine heterogeneity. Br Med J 313:862
12. Mitsuma S, Yoshizawa H, Ito K, et al (1994) 5-S adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells. Immunology 83:45
13. Pandolfino MC, Labarrière N, Tessier MH, et al (2001) High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: Predictability and relation with disease advancement. Cancer Immunol Immunother 50:134
14. Rosenberg SA, Packard BS, Aebersold PM, et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 319:1676
15. Rosenberg SA, Yannelli JR, Yang JC, et al (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159
16. Ruiz-Cabello F, Klein E, Garrido F (1991) MHC antigens in human tumors. Immunol Lett 29:181
17. Sankoh AJ, Huque MF, Dubey SD (1997) Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16:2529
18. Seo N, Hayakawa S, Takigawa M, Tokura Y (2001) Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103:449
19. Serraino D, Fratino L, et al (1998) Epidemiological aspects of cutaneous malignant melanoma [review]. Oncol Rep 5:905
20. Tessier MH, Pandolfino MC, Jotereau F, et al (1996) Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma. Eur J Cancer 32A:735
21. Van Belle PA, Elenitsas R, et al (1999) Progression-related expression of beta 3 integrin in melanomas and nevi. Hum Pathol 30:562
22. Withehead J (1992) The Design and Analysis of Sequential Clinical Trials. 2nd Edition, Ellis Horwood